Table 3.
Statistically Significant Adverse Events – Antimuscarinic versus Tolterodine IR/ER or Oxybutynin IR
| Outcome | Total Comparisons/Studies | All Studies | Oxybutynin ER | Solifenacin | Total Studies | Oxybutynin ER | Total Studies | Fesoterodine |
|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | RR (95% CI)(Minassian et al., 2007) | RR (95% CI)(Herschorn et al., 2011) | RR (95% CI)(Sand et al., 2004) | RR (95% CI)(DuBeau et al., 2012) | ||||
|
| ||||||||
| Versus Oxybutynin IR | Versus Tolterodine IR | Versus Tolterodine ER | ||||||
| AEs | 2 | 0.78
(0.61–0.98) NNH=6.0 |
0.94 (0.59–1.49) | 0.73
(0.56–0.94) NNH=3.9 |
0 | -- | 1 | 1.37 (1.21–1.55) NNH =6.7 |
| Dry Mouth | 2 | 0.56
(0.38–0.83) NNH=3.3 |
0.69(0.40–1.18) | 0.46
(0.27–0.78) NNH=2.3 |
1 | 1.18 (0.72–1.93) | 1 | 2.13 (1.69–2.69) NNH =6.0 |
| Dry Mouth, Moderate | 1 | 0.05
(0.00–0.86) NNH=3 |
-- | 0.05
(0.00–0.86) NNH=3 |
0 | -- | 0 | -- |
| Treatment-related AEs | 1 | 0.68
(0.49–0.96) NNH=3.6 |
-- | 0.68
(0.49–0.96) NNH=3.6 |
0 | -- | 0 | -- |
Only reported if both studies reported outcomes
*
I2 >25%
AEs = Adverse Events; CI = confidence intervals; ER = extended release; IR = immediate release; NNH = Number Needed to Harm; RR= rate ratio